JP2025506731A5 - - Google Patents
Info
- Publication number
- JP2025506731A5 JP2025506731A5 JP2024549148A JP2024549148A JP2025506731A5 JP 2025506731 A5 JP2025506731 A5 JP 2025506731A5 JP 2024549148 A JP2024549148 A JP 2024549148A JP 2024549148 A JP2024549148 A JP 2024549148A JP 2025506731 A5 JP2025506731 A5 JP 2025506731A5
- Authority
- JP
- Japan
- Prior art keywords
- population
- seq
- amino acid
- acid sequence
- effector cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263312507P | 2022-02-22 | 2022-02-22 | |
| US63/312,507 | 2022-02-22 | ||
| US202263418105P | 2022-10-21 | 2022-10-21 | |
| US63/418,105 | 2022-10-21 | ||
| PCT/US2023/013537 WO2023163956A2 (en) | 2022-02-22 | 2023-02-21 | Kir3dl3 inhibitors and immune cell activating agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025506731A JP2025506731A (ja) | 2025-03-13 |
| JP2025506731A5 true JP2025506731A5 (https=) | 2026-03-03 |
Family
ID=87766832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024549148A Pending JP2025506731A (ja) | 2022-02-22 | 2023-02-21 | Ｋｉｒ３ｄｌ３阻害剤及び免疫細胞活性化剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250171533A1 (https=) |
| EP (1) | EP4482526A4 (https=) |
| JP (1) | JP2025506731A (https=) |
| KR (1) | KR20250005988A (https=) |
| AU (1) | AU2023225596A1 (https=) |
| CA (1) | CA3243330A1 (https=) |
| IL (1) | IL314839A (https=) |
| MX (1) | MX2024009960A (https=) |
| WO (1) | WO2023163956A2 (https=) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2992551A1 (en) * | 2015-07-21 | 2017-01-26 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| DK3515478T3 (da) * | 2016-09-21 | 2024-05-21 | Nextcure Inc | Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf |
| JP7716393B2 (ja) * | 2019-10-04 | 2025-07-31 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 抗ｋｉｒ３ｄｌ３抗体およびそれらの使用 |
| IL291897A (en) * | 2019-10-04 | 2022-06-01 | Albert Einstein College Medicine | Kir3dl3 inhibitory receptor of the immune system and its uses |
-
2023
- 2023-02-21 KR KR1020247031430A patent/KR20250005988A/ko active Pending
- 2023-02-21 EP EP23760581.1A patent/EP4482526A4/en active Pending
- 2023-02-21 AU AU2023225596A patent/AU2023225596A1/en active Pending
- 2023-02-21 US US18/839,953 patent/US20250171533A1/en active Pending
- 2023-02-21 MX MX2024009960A patent/MX2024009960A/es unknown
- 2023-02-21 CA CA3243330A patent/CA3243330A1/en active Pending
- 2023-02-21 IL IL314839A patent/IL314839A/en unknown
- 2023-02-21 JP JP2024549148A patent/JP2025506731A/ja active Pending
- 2023-02-21 WO PCT/US2023/013537 patent/WO2023163956A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12384850B2 (en) | Guidance and navigation control proteins and method of making and using thereof | |
| JP6650537B2 (ja) | 抗ｃｔｌａ−４抗体 | |
| US11167029B2 (en) | Combination of a CD30XCD16 antibody with a PD-1 antagonist for therapy | |
| JP2023093469A (ja) | 抗ｃｄ１６ａ抗体のサイトカインとの組み合わせ | |
| JP2024023317A (ja) | 二重特異性抗体の組成物及びその使用方法 | |
| JP2025065211A (ja) | 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ | |
| JP2022512917A5 (https=) | ||
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| CN116425876A (zh) | Bcma结合分子及其使用方法 | |
| JP2023519099A5 (https=) | ||
| AU2019314452B2 (en) | Chimeric antigen receptor therapy T cell expansion kinetics and uses thereof | |
| CN118593691A (zh) | 施用嵌合抗原受体免疫疗法的方法 | |
| KR20200128014A (ko) | 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법 | |
| WO2021084064A1 (en) | Sequential anti-cd19 therapy | |
| JP2018524404A (ja) | Ｎｋ細胞殺傷活性を増強する方法および医薬組成物 | |
| JP2023554422A (ja) | がんの治療のための多重特異性抗体 | |
| JP2025506731A5 (https=) | ||
| Lam et al. | Pharmacokinetics and pharmacodynamics of immunotherapy | |
| US20240190965A1 (en) | Targeting anti-human pd 1h/vista to treat hematologic disorders | |
| TWI917318B (zh) | 靶向ｄｌｌ３的嵌合抗原受體和結合劑 | |
| WO2025106736A2 (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer | |
| AU2024225483A1 (en) | Combination of btn3a activating antibody and immune checkpoint inhibitors | |
| EA049485B1 (ru) | Комбинация ингибиторов pd-1 и ингибиторов lag-3 для повышения эффективности при лечении рака | |
| EA048837B1 (ru) | Ступенчатая анти-cd19 терапия | |
| HK40063038B (zh) | 靶向dll3的嵌合抗原受体和结合剂 |